Trials / Completed
CompletedNCT02721472
Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Theravia · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the relationship between plasma DNA levels and micro- and macro-circulatory vascular remodelling in patients with sickle cell disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | micro- and macro-circulatory vascular remodelling measures not practice in routine care | Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity |
| PROCEDURE | Biological measures not practice in routine care | Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1 |
Timeline
- Start date
- 2016-05-17
- Primary completion
- 2019-11-14
- Completion
- 2019-11-14
- First posted
- 2016-03-29
- Last updated
- 2020-01-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02721472. Inclusion in this directory is not an endorsement.